Heroin anticraving medications: a systematic review
Effectiveness bank home page. Opens new windowReview analysis

This entry is our analysis of a review or synthesis of research findings added to the Effectiveness Bank. The original review was not published by Findings; click Title to order a copy. Free reprints may be available from the authors – click prepared e-mail. The summary conveys the findings and views expressed in the review.

Links to other documents. Hover over for notes. Click to highlight passage referred to. Unfold extra text Unfold supplementary text
Copy title and link | Comment/query |

Heroin anticraving medications: a systematic review.

Fareed A., Vayalapalli S., Casarella J. et al.
American Journal of Drug and Alcohol Abuse: 2010, 36(6), p. 332–341.
Unable to obtain a copy by clicking title? Try asking the author for a reprint by adapting this prepared e-mail or by writing to Dr Fareed at ayman.fareed@va.gov.

The observation that craving can precipitate relapse to heroin use or drop-out even among methadone-maintained patients led to this search for evidence that other medications can help suppress the urge to use; buprenorphine had the most extensive positive research record to date.

Summary Background Heroin craving is a trigger for relapse and dropping out of treatment. Methadone has been the standard medication for the management of heroin craving.

Objectives We explored the medication options other than methadone which may have heroin anti-craving properties.

Methods To be selected for the review, articles had to include outcome measures of the effect of the studied medication on subjective and/or objective opiate craving and be of the following two types:
• randomised, controlled, and/or double-blind clinical trials (RCTs) examining the relationship between the studied medication and heroin craving;
• nonrandomised and observational studies (NRSs) examining the relationship between the studied medication and heroin craving.

Thirty-three articles were initially included in the review. Twenty-one were excluded because they did not meet the inclusion criteria. We present the results of 12 articles that met all the inclusion criteria.

Results Some new medications have been under investigation and seem promising for the treatment of opiate craving. Buprenorphine is the second most studied medication after methadone for its effect on opiate craving. At doses above 8mg daily, it seems very promising and practical for managing opiate craving in patients receiving long-term opioid maintenance treatment.

Conclusions and Scientific Significance In doses higher than 8mg daily, buprenorphine is an appropriate treatment for opiate craving. More research with rigorous methodology is needed to study the effect of buprenorphine on heroin craving. Also more studies are needed to directly compare buprenorphine and methadone with regard to their effects on heroin craving.

Last revised 18 January 2011

Open Effectiveness Bank home page

Top 10 most closely related documents on this site. For more try a subject or free text search

MATRIX CELL 2018 Drug Treatment Matrix cell B3: Practitioners; Medical treatment

DOCUMENT 2015 American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use

MATRIX CELL 2018 Drug Treatment Matrix cell A3: Interventions; Medical treatment

REVIEW 2009 Pharmacotherapies for the treatment of opioid dependence: efficacy, cost-effectiveness and implementation guidelines

STUDY 2017 Effectiveness of injectable extended-release naltrexone vs daily buprenorphine–naloxone for opioid dependence: A randomized clinical noninferiority trial

DOCUMENT 2017 Drug misuse and dependence: UK guidelines on clinical management

DOCUMENT 2018 Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families: Treatment Improvement Protocol: TIP 63

REVIEW 2012 BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP

STUDY 2019 Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

DOCUMENT 2009 Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence